Franklin Hoke | Jun 21, 1992 | 6 min read
But it's still unclear which new approaches in human therapeutics will pay off big; cancer and neuroscience are among the contenders Despite the enormous amount of money invested in research and development of biotechnology-derived human therapeutics in the past two decades or so, biotech industry participants and observers say the future is still unclear. Only 21 biotech drugs have been released so far, and many of those are bioengineered versions of substances that have been known and used